Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Joachim Brendel	02/26/2008
Heinrich Englert	02/25/2008
Klaus Wirth	03/07/2008
Michael Wagner	03/03/2008
Jean-Marie Ruxer	03/06/2008
Fabienne Pilorge	03/14/2008

RECEIVING PARTY DATA

Name:	Sanofi-Aventis
Street Address:	174 Avenue de France
City:	Paris
State/Country:	FRANCE
Postal Code:	75013

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	11954396

CORRESPONDENCE DATA

Fax Number: (908)231-2626

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 908-231-2551

Email: maribel.mendez@sanofi-aventis.com

Correspondent Name: Ronald G. Ort Address Line 1: Route 202-206

Bridgewater, NEW JERSEY 08807 Address Line 4:

ATTORNEY DOCKET NUMBER:	DE2005/026 US CNT
NAME OF SUBMITTER:	Maribel Mendez
	PATENT

500532859 **REEL: 020911 FRAME: 0050**

Total Attachments: 4 source=DE2005-026USCNTAssignment#page1.tif source=DE2005-026USCNTAssignment#page2.tif source=DE2005-026USCNTAssignment#page3.tif source=DE2005-026USCNTAssignment#page4.tif

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Joachim Brendel, Landgrabenstraße 23, 61118 Bad Vilbel, Germany
- 2) Dr. Heinrich Englert, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Klaus Wirth, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 4) Dr. Michael Wagner, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 5) Dr. Jean-Marie Ruxer, c/o sanofi-aventis, Département Brevets, 174, Avenue de France, 75013 Paris, France
- 6) Fabienne Pilorge, c/o sanofi-aventis, Département Brevets, 174, Avenue de France, 75013 Paris, France

The inventors are citizens of: 1)-4) Germany; 5)-6) France

hereby sell, assign, and transfer unto sanofi-aventis, a corporation organized under the laws of France, located at 174 avenue de France, 75013 Paris, France,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 11/954,396

filed: December 12, 2007

entitled: Substituted heterocycles, their use as medicament, and pharmaceutical

preparations comprising them

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s):	Jen Mate: <u>× Feb. 26, 2008</u>
2 nd :	Date:
3 rd :	Date:
4 th :	Date:
5 th :	Date:
6 th :	Date:

DE2005/026 US CNT

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Joachim Brendel, Landgrabenstraße 23, 61118 Bad Vilbel, Germany
- 2) Dr. Heinrich Englert, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Klaus Wirth, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 4) Dr. Michael Wagner, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 5) Dr. Jean-Marie Ruxer, c/o sanofi-aventis, Département Brevets, 174, Avenue de France, 75013 Paris, France
- 6) Fabienne Pilorge, c/o sanofi-aventis, Département Brevets, 174, Avenue de France, 75013 Paris, France

The inventors are citizens of: 1)-4) Germany; 5)-6) France

hereby sell, assign, and transfer unto sanofi-aventis, a corporation organized under the laws of France, located at 174 avenue de France, 75013 Paris, France,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 11/954,396

filed: December 12, 2007

entitled: Substituted heterocycles, their use as medicament, and pharmaceutical

preparations comprising them

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s):

1 st :		Date:
2 nd :	Helisich Aleghi	Date: 25 - 2 - 08
3 rd :	The with	Date: 7.3.08
4 th :	Michael Wagne	Date: 3.3. 2008
5 th :		Date:
6 th :		Date:

DE2005/026 US CNT

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Joachim Brendel, Landgrabenstraße 23, 61118 Bad Vilbel, Germany
- 2) Dr. Heinrich Englert, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Klaus Wirth, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 4) Dr. Michael Wagner, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 5) Dr. Jean-Marie Ruxer, c/o sanofi-aventis, Département Brevets, 174, Avenue de France, 75013 Paris, France
- 6) Fabienne Pilorge, c/o sanofi-aventis, Département Brevets, 174, Avenue de France, 75013 Paris, France

The inventors are citizens of: 1)-4) Germany; 5)-6) France

hereby sell, assign, and transfer unto sanofi-aventis, a corporation organized under the laws of France, located at 174 avenue de France, 75013 Paris, France,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 11/954,396

filed: December 12, 2007

entitled: Substituted heterocycles, their use as medicament, and pharmaceutical

preparations comprising them

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s):

1 st :	Date:
2 nd :	Date:
3 rd :	Date:
4 th :	Date:
5 th :	Date:
6 th :	Date:

DE2005/026 US CNT

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged.

I/we

- 1) Dr. Joachim Brendel, Landgrabenstraße 23, 61118 Bad Vilbel, Germany
- 2) Dr. Heinrich Englert, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Klaus Wirth, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 4) Dr. Michael Wagner, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 5) Dr. Jean-Marie Ruxer, c/o sanofi-aventis, Département Brevets, 174, Avenue de France, 75013 Paris. France
- 6) Fabienne Pilorge, c/o sanofi-aventis, Département Brevets, 174, Avenue de France, 75013 Paris, France

The inventors are citizens of: 1)-4) Germany; 5)-6) France

hereby sell, assign, and transfer unto sanofi-aventis. a corporation organized under the laws of France, located at 174 avenue de France, 75013 Paris, France,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 11/954,396

filed: **December 12, 2007**

Substituted heterocycles, their use as medicament, and pharmaceutical entitled:

preparations comprising them

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s): 1st: _______ Date: _____

2nd: Date:

3rd: Date: _____ Date: _____

_____ Date: _____

Date: 14/03/2008

PATENT REEL: 020911 FRAME: 0055

RECORDED: 05/07/2008